{
  "docId": "019dd923-5e88-73ef-bd5a-c8877c2d773b",
  "docSlug": "62a053437732d31d",
  "documentTitle": "250114 FRE prsn JPM SFO 0",
  "authorId": "JPMorgan",
  "authorName": "Fresenius",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 8,
  "pageCount": 15,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "kpi_dashboard",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The slide uses a split-screen approach to contrast European market performance with US commercial milestones.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "line_chart",
    "timeline_visual",
    "icon_grid"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-c8877c2d773b/8",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-c8877c2d773b",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-c8877c2d773b.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-c8877c2d773b#slide-8",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Largely moving from parity to exclusive IL6/Tocilizumab coverage in '25",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-28a9-71be-806c-d37f1b7d37db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.04,
        "y": 0.58
      },
      "kind": "chart",
      "text": "Tyenne market shares",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76b4ca32-1ee1-4dd2-9a33-0fc8d32e5728",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.35,
        "x": 0.62,
        "y": 0.29
      },
      "kind": "chart",
      "text": "US Milestones",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "743e8619-c3fc-4a30-b42e-d5fa5e0197e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.14,
        "x": 0.43,
        "y": 0.53
      },
      "kind": "image",
      "text": "Tyenne logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8650b85e-4dbd-4969-8874-0dd3262aa2f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.105,
        "y": 0.33
      },
      "kind": "list",
      "text": "Launched in 19 EU countries, UK & KSA (Q3/24); 21% market share in EU5 (Oct 24); Essentially all GER sick funds contracted; 95% tender win rate in FRA",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ba20649-69ac-4f1c-97a0-c1eebf558d55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.62,
        "y": 0.6
      },
      "kind": "list",
      "text": "Shipping under >35 payor client agreements; Permanent, product-specific Q-Code and pass-through payment status granted; Contracted several large PBMs/IDNs; Largely moving from parity to exclusive IL6/Tocilizumab coverage in '25",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b06121bf-9256-4a7b-bfb5-20dc5437f081",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "market share: 21%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-28a9-71be-806c-d476cbf7c405",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.038,
        "y": 0.105
      },
      "kind": "title",
      "text": "Building strong momentum with Tyenne",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8f8a38d-02cc-47af-9955-0547f7cf018d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 8,
      "beatId": "96ffe88c-8d2a-4d23-a98c-19240d899804",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 8-12 provide data and metrics on Fresenius Kabi's momentum, growth, and financial progression.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "0f7b9246-98b4-450f-9b9b-af0a2ddf2192",
      "evidence": "Slides 6-10 emphasize the need for transformation and growth.",
      "position": 0,
      "objective": "Highlighting the importance of transformation",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}